Literature DB >> 2631425

[Use of low dose lasers in physiatry].

L Konstantinović, M Antonić, M Mihajlović, D Vucetić.   

Abstract

The prospective study comprised 105 patients treated for six months in the out-patient and in-patient institutions suffering from the syndrome manifested in pain and disturbed functions due to the diseases of the nerve-muscle and bone-connective tissue systems. The group of patients with the vertebro-basilar syndrome was selected by a single-blind controlled trial while the rest constituted the group whose results were preliminary presented. Two modes of laser photobiostimulation were applied: local stimulation and stimulation of acupuncture points. Evaluation of effects were performed by following up subjective troubles, clinical examinations, laboratory analyses and in patients with the vertebro-basilar syndrome by rheoencephalography in addition. The application of the mentioned methods in different pathological states have shown positive results in 78% of patients with analgesic, spasmolytic and antiadematous effects. In patients with the vertebro-basilar syndrome disappearance of subjective troubles was followed by the improved perfusion in the vertebro-basilar system with the mean increase of the amplitude of the rheoencephalographic curve of 0.063 +/- 0.018 oms and the mean shortening of the anacrotic phase of 0.048 +/- 0.019 seconds.

Entities:  

Mesh:

Year:  1989        PMID: 2631425

Source DB:  PubMed          Journal:  Vojnosanit Pregl        ISSN: 0042-8450            Impact factor:   0.168


  1 in total

1.  Randomized, blinded, controlled trial on effectiveness of photobiomodulation therapy and exercise training in the fibromyalgia treatment.

Authors:  Mariana Moreira da Silva; Regiane Albertini; Paulo de Tarso Camillo de Carvalho; Ernesto Cesar Pinto Leal-Junior; Sandra Kalil Bussadori; Stella Sousa Vieira; Danilo Sales Bocalini; Luis Vicente Franco de Oliveira; Vanessa Grandinetti; José Antonio Silva; Andrey Jorge Serra
Journal:  Lasers Med Sci       Date:  2017-11-23       Impact factor: 3.161

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.